NEW YORK (GenomeWeb News) – Medical diagnostic company Myconostica said yesterday that it has received a license from Health Canada to sell its Aspergillus molecular diagnostic test in Canada.
Myconostica's MycAssay Aspergillus detects Aspergillus DNA in lower respiratory tract samples. Results of the test aid physicians in diagnosing immunocompromised patients suspected of having an infection caused by the fungus.
When MycAssay is used in conjunction with Myconostica's extraction system, MycXtra, a result can be obtained within three hours of sample receipt, the company said.
In conjunction with the announcement, Myconostica, based in Manchester, UK, also said that it has signed an agreement with Inverness Medical Canada, a subsidiary of Inverness Medical Innovations, to exclusively distribute Myconostica's products in Canada.